Navigation Links
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Date:5/21/2009

y with local communities and the natural environment.

For additional information, please visit www.otsuka-global.com.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group comprises 153 companies and employs approximately 36,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned 955.9 billion yen (approx. US $9.7 billion*) in annual revenues in fiscal 2008.

* Exchange rate as of March 31, 2009.

About Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Otsuka Pharmaceutical Development and Commercialization, Inc. is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world with a strong commitment to research and development in the areas of cardiovascular, gastrointestinal, respiratory, renal and neuroscience systems, and to treat cancer and ophthalmic disorders. OPDC is part of the Otsuka Pharmaceutical Group of companies. For additional information, please visit www.otsuka-us.com.

About Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular, oncologic,
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Denver, Colorado (PRWEB) July 10, 2014 ... countries will gather in Copenhagen this July 13-17 ... discoveries bringing the world closer to breakthroughs in ... is the world’s largest conference of its kind. ... program, AAIC serves as a catalyst for generating ...
(Date:7/10/2014)... July 10, 2014 CBPartners, a global ... has launched a new website. The redesigned site ... increased access to the firm’s thought pieces, blog posts, ... ideal platform to showcase our insights, capabilities, and to ... CBPartners’ Chief Executive Officer, Cyrus Chowdhury. “An enhanced ...
(Date:7/10/2014)... 10, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, ... over allegations that the woman’s hidden, aggressive leiomyosarcoma ... morcellator used during a routine laparoscopic supracervical hysterectomy ... Wolf Medical Instruments Corporation over its Wolf Power ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2
... ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem,(International) ... (NASDAQ: NRMX ; TSX: NRM), announces ... pursue the drug development program for its ... approval for,the treatment of Amyloid A (AA) ...
... VELCADE, melphalan and prednisone, reported a 32 percent complete remission rate ... ... CAMBRIDGE, Mass., March 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ... clinical trial of the combination therapy,VELCADE, melphalan and prednisone (VcMP) in ...
... notes due June 2008 ... expenses going forward Projects Zevalin(R) net ... 13 Seattle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MTA) ... twelve months ended December 31,2007., Recent Events, Announced ...
... Health Parity on Capitol Hill, WASHINGTON, March 12 ... Her Arms (TWLOHA) with the Mental Health Liaison,Group will ... Hill in,room B369 Rayburn House Office Building. It will ... Addiction Equity Act, an important,civil rights victory that begins ...
... Not Good Enough, WASHINGTON, March 12 Today, ... the,health-based National Ambient Air Quality Standard for ozone. We ... cannot. The standard announced,today, although an improvement, falls far ... are unable to celebrate half measures when the risks ...
... Award for ... Innovation in Healthcare Research, SACRAMENTO, Calif., March 12 ... ratios in California,hospitals revealed little impact on patient outcomes in ... the March 2008 issue of,Policy, Politics & Nursing Practice, a ...
Cached Medicine News:Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 2Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 4
(Date:7/10/2014)... July 10, 2014 Integrated Silicon Solution, Inc. ... memory and analog IC solutions, today announced that it ... 24, 2014, at 7:00 a.m. Pacific Time (10:00 a.m. ... the fiscal 2014 third quarter ended June 30, 2014. ... dial 1-888-556-4997 before 6:50 a.m. Pacific time on July ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Inc. today announced the completion of subject dosing ... and bioavailability after administration of two proprietary formulations ... collaboration with the University of Minnesota and James ... experts in clinical research of the nasal delivery ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals ... 500 mg, the generic version of Novartis, Famvir® Tablets, a ... sales of approximately $196 million for the 12 months ending ... Currently, Mylan has 165 ANDAs pending FDA approval representing $98.5 ...
Cached Medicine Technology:Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam 2
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: